Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "gemcitabine"

18 News Found

Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
News | July 05, 2023

Venus Remedies gets marketing approvals for oncology medicine from 4 key markets

With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503


Venus Remedies bolsters its position in oncology space with marketing approval from Philippines, Iraq
Drug Approval | May 10, 2023

Venus Remedies bolsters its position in oncology space with marketing approval from Philippines, Iraq

The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region


Venus Remedies secures marketing authorization from UK MHRA for Cisplatin
News | April 27, 2023

Venus Remedies secures marketing authorization from UK MHRA for Cisplatin

Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country


Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData
Drug Approval | February 27, 2023

Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData

The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country


Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine
News | February 23, 2023

Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine

The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability


Sakar Healthcare starting Liquid & Lyophilised Injection unit
News | January 04, 2023

Sakar Healthcare starting Liquid & Lyophilised Injection unit

The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment


Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Diagnostic Center | December 12, 2022

Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes


China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Drug Approval | June 12, 2022

China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer

Tislelizumab is now approved in nine indications in China